Vascular Biogenics Ltd. (VBLT)
Market Cap | 15.40M |
Revenue (ttm) | 545,000 |
Net Income (ttm) | -24.52M |
Shares Out | 70.50M |
EPS (ttm) | 0.33 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 916,469 |
Open | 0.225 |
Previous Close | 0.230 |
Day's Range | 0.213 - 0.230 |
52-Week Range | 0.101 - 2.200 |
Beta | 0.68 |
Analysts | Hold |
Price Target | 5.50 (+2,417.16%) |
Earnings Date | May 26, 2023 |
About VBLT
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III ... [Read more]
Financial Performance
In 2022, VBLT's revenue was $658,000, a decrease of -14.32% compared to the previous year's $768,000. Losses were -$32.30 million, 7.97% more than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VBLT stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 2,417.16% from the latest price.
News

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals Recently filed S-4 registration...

VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a cor...

VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Mod...

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
REHOVOT, Israel--(BUSINESS WIRE)-- #COP26--Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility ...

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT
NEW YORK , Feb. 27, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm r...

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular Bioge...

VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vascular Biogenics Ltd. (NASDAQ: VBLT) and Notable Labs, Inc. is fair to Vascular share...

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Med...

VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today ...

VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued progress on previously announced strategic process to maximize shareholder value Continued progress on previously announced strategic process to maximize shareholder value

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today...

VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor

VBL Therapeutics Announces Workforce Reduction
TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, toda...

Why Vascular Biogenics Stock Is Plunging
Vascular Biogenics Ltd (NASDAQ: VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet t...

VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - - Trial Did Not Meet Statistical Significance on Improve...

VBL Therapeutics to Participate in the Jefferies Healthcare Conference
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-...

VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for diffi...

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for diffi...

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-t...

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
TEL AVIV, Israel and NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif...

VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
TEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics f...

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif...

VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif...